{"id":{"repo_id":"rowan","oai_identifier":"oai:rdw.rowan.edu:etd-3865"},"canonical_url":"https://search.ndltd.org/etd/rowan/oai:rdw.rowan.edu:etd-3865","repository":{"repo_id":"rowan","name":"Rowan University","base_url":"https://rdw.rowan.edu/do/oai/"},"display":{"title":"Experimental pharmacotherapies in models of alcohol addiction","abstract":"The USA faces $220 billion economic loss and eighty thousand deaths per year due to alcohol abuse while affecting more than 15 million people, making it the third largest life-style related cause of death. The U.S. FDA has approved four medications namely, disulfiram, acamprosate, oral naltrexone, and injectable long-acting naltrexone. These existing drugs are trashed with side effects, have a low success rate, indicating a demand for new potential drugs. We studied the effects of the CB1 negative allosteric modulator, PSNCBAM-1, and the dopamine D4 receptor antagonist, L-745,870 in mouse models of alcohol addiction. PSNCBAM-1 did not significantly reduce CPP for 2.0 g/kg ethanol or alter locomotor activity, but its dose-dependently attenuated oral ethanol self-administration at the dose of 30 mg/kg. 18 and 30 mg/kg PSNCBAM-1 significantly reduced self-administration of palatable food reward. These results suggest, PSNCBAM-1 produces a non-specific anhedonic effect that may preclude its use in AUD. L-745,870 did not significantly affect conditioned place preference for 2.0 g/kg ethanol, ethanol self-administration, locomotor activity in an open field, or co-ordination in the rotarod test. These results suggest that D4R antagonism does not alter the rewarding value of ethanol.","abstract_html":"The USA faces $220 billion economic loss and eighty thousand deaths per year due to alcohol abuse while affecting more than 15 million people, making it the third largest life-style related cause of death. The U.S. FDA has approved four medications namely, disulfiram, acamprosate, oral naltrexone, and injectable long-acting naltrexone. These existing drugs are trashed with side effects, have a low success rate, indicating a demand for new potential drugs. We studied the effects of the CB1 negative allosteric modulator, PSNCBAM-1, and the dopamine D4 receptor antagonist, L-745,870 in mouse models of alcohol addiction. PSNCBAM-1 did not significantly reduce CPP for 2.0 g/kg ethanol or alter locomotor activity, but its dose-dependently attenuated oral ethanol self-administration at the dose of 30 mg/kg. 18 and 30 mg/kg PSNCBAM-1 significantly reduced self-administration of palatable food reward. These results suggest, PSNCBAM-1 produces a non-specific anhedonic effect that may preclude its use in AUD. L-745,870 did not significantly affect conditioned place preference for 2.0 g/kg ethanol, ethanol self-administration, locomotor activity in an open field, or co-ordination in the rotarod test. These results suggest that D4R antagonism does not alter the rewarding value of ethanol.","abstract_has_math":false,"creators":["Sumi, Mousumi Akter"],"institution":null,"degree_name":"M.S. Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"Chemistry & Biochemistry","degree_department":null,"school":null,"contributors":["Keck, Thomas M.","Grinias, James","Fischer, Bradford D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:59:18Z","subjects":["Addiction","Alcohol use disorder","CB1 negative allosteric modulator","condition place preference","Dopamine D4 antagonist","Two bottle choice","Alcoholism--Treatment","Drug development","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://rdw.rowan.edu/etd/2863","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://rdw.rowan.edu/etd/2863","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://rdw.rowan.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ardw.rowan.edu%3Aetd-3865","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Keck, Thomas M.","Grinias, James","Fischer, Bradford D."]},{"key":"dc:creator","label":"Author","values":["Sumi, Mousumi Akter"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2021-01-22T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2021-01-20T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry & Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S. Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Addiction","Alcohol use disorder","CB1 negative allosteric modulator","condition place preference","Dopamine D4 antagonist","Two bottle choice","Alcoholism--Treatment","Drug development","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://rdw.rowan.edu/etd/2863"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The USA faces $220 billion economic loss and eighty thousand deaths per year due to alcohol abuse while affecting more than 15 million people, making it the third largest life-style related cause of death. The U.S. FDA has approved four medications namely, disulfiram, acamprosate, oral naltrexone, and injectable long-acting naltrexone. These existing drugs are trashed with side effects, have a low success rate, indicating a demand for new potential drugs. We studied the effects of the CB1 negative allosteric modulator, PSNCBAM-1, and the dopamine D4 receptor antagonist, L-745,870 in mouse models of alcohol addiction. PSNCBAM-1 did not significantly reduce CPP for 2.0 g/kg ethanol or alter locomotor activity, but its dose-dependently attenuated oral ethanol self-administration at the dose of 30 mg/kg. 18 and 30 mg/kg PSNCBAM-1 significantly reduced self-administration of palatable food reward. These results suggest, PSNCBAM-1 produces a non-specific anhedonic effect that may preclude its use in AUD. L-745,870 did not significantly affect conditioned place preference for 2.0 g/kg ethanol, ethanol self-administration, locomotor activity in an open field, or co-ordination in the rotarod test. These results suggest that D4R antagonism does not alter the rewarding value of ethanol."]},{"key":"dc:title","label":"Title","values":["Experimental pharmacotherapies in models of alcohol addiction"]}]}],"canonical_facts":{"dc:contributor":["Keck, Thomas M.","Grinias, James","Fischer, Bradford D."],"dc:creator":["Sumi, Mousumi Akter"],"dc:date.available":["2021-01-22T08:00:00Z"],"dc:date.created":["2021-01-20T08:00:00Z"],"dc:description.abstract":["The USA faces $220 billion economic loss and eighty thousand deaths per year due to alcohol abuse while affecting more than 15 million people, making it the third largest life-style related cause of death. The U.S. FDA has approved four medications namely, disulfiram, acamprosate, oral naltrexone, and injectable long-acting naltrexone. These existing drugs are trashed with side effects, have a low success rate, indicating a demand for new potential drugs. We studied the effects of the CB1 negative allosteric modulator, PSNCBAM-1, and the dopamine D4 receptor antagonist, L-745,870 in mouse models of alcohol addiction. PSNCBAM-1 did not significantly reduce CPP for 2.0 g/kg ethanol or alter locomotor activity, but its dose-dependently attenuated oral ethanol self-administration at the dose of 30 mg/kg. 18 and 30 mg/kg PSNCBAM-1 significantly reduced self-administration of palatable food reward. These results suggest, PSNCBAM-1 produces a non-specific anhedonic effect that may preclude its use in AUD. L-745,870 did not significantly affect conditioned place preference for 2.0 g/kg ethanol, ethanol self-administration, locomotor activity in an open field, or co-ordination in the rotarod test. These results suggest that D4R antagonism does not alter the rewarding value of ethanol."],"dc:identifier":["https://rdw.rowan.edu/etd/2863"],"dc:subject":["Addiction","Alcohol use disorder","CB1 negative allosteric modulator","condition place preference","Dopamine D4 antagonist","Two bottle choice","Alcoholism--Treatment","Drug development","Pharmacy and Pharmaceutical Sciences"],"dc:title":["Experimental pharmacotherapies in models of alcohol addiction"],"thesis:degree_discipline":["Chemistry & Biochemistry"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S. Pharmaceutical Sciences"]},"updated_at":"2026-11-19T08:59:18Z"}